FDA · Life Science & Pharma: GxP - CSV & Data Integrity

Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations (FDA guidance)

Final Quality foundations · Guidance Last verified: not yet · Source last checked 3 Nov 2026

Issued by
FDA
Category
Quality foundations
Sub Category
Guidance
Legal weight
Guidance & Q&A
Reuse
Public domain

FDA's guidance showing how a modern quality system fits with the US drug GMP rules.

How to read this page

Details: Guide Definitions: every term and label explained

Lifecycle

Solid steps have happened. A dashed step is expected, and it is not a fact. Only dated steps in our record appear here.

  1. Done · 2 Oct 2006Final guidance issued

In plain English

FDA guidance to help manufacturers use modern quality systems and risk management to meet the CGMP regulations in 21 CFR parts 210 and 211.

Summary drafted with AI assistance. Not yet reviewed by the SME Reviewer. Read the official text before acting.

Context and history

FDA issued this guidance on 2 October 2006 to help manufacturers use modern quality systems and risk management to meet the drug CGMP rules. It shows how a quality systems model fits with parts 210 and 211.

Who and what it applies to

Manufacturers of human and veterinary drugs, including biological products, under parts 210 and 211.

What it contains

Background and purpose
Why FDA promotes modern quality systems, and how this guidance relates to CGMP.
CGMPs and modern quality systems
Quality, quality by design and product development, quality risk management, CAPA, change control, the quality unit, and the six-system inspection model.
Management responsibilities
Provide leadership, structure the organisation, build the quality system, set policies and objectives, and review the system.
Resources
General arrangements, personnel development, facilities and equipment, and control of outsourced operations.
Manufacturing
Design and document products and processes, examine inputs, perform and monitor operations, and address nonconformities.
Evaluation activities
Analyse data for trends, conduct internal audits, use quality risk management, and take corrective action, preventive action and improvement steps.

Key points

  • A quality system complements CGMP, and does not replace it.
  • Management is expected to lead.
  • The model extends to outsourced operations.
  • Its six-system inspection model explains how FDA looks at a firm.
  • FDA cited it in the 2026 warning letter on AI use.

In practice

General reading, not advice. This is drafted with AI and may not fit your situation. It does not replace the official text, your own quality system or qualified advice, and an inspector may take a different view.

  • Use its four parts to place computerised systems and data integrity inside your quality system.
  • Use trend analysis of audit trail and deviation data as evidence of evaluation.

Read from the source document on 1 Nov 2026. This is our own description, not the official text. Check the full dated history in the change log below.

Change log

Key dated events only, not a complete history. Status after is the status once that event happened. Event kinds explained

DateEventStatus afterSource
2 Oct 2006Final guidance issuedFinalSource for Final guidance issued

How other documents connect to this one. Links explained

Compare with all linked instruments

Official source

The official text always prevails over anything on this site.

Read the official text

Source: FDA. Public domain.

Stay updated

Newsletter signup opens at launch.